clinical trial · NCT07445308
The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.
Shenyang Sunshine Pharmaceutical Co., LTD.·phase2·not yet recruiting·n = 120
NMIBCSPGL008
brief summary
The goal of clinical trial is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With on-Muscle-Invasive Bladder Cancer. The main questions it aims to answer are: 1. Determine the recommend Phase II dose of SPGL008 Alone or in Combination With BCG.To 2. Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.
started
Mar 12, 2026
primary completion
Nov 21, 2028
completion
Dec 21, 2029
last updated
Mar 3, 2026
official title
Phase I/II Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of SPGL008 as Monotherapy or in Combination With BCG in Patients With Non-Muscle-Invasive Bladder Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol